AG百家乐大转轮-AG百家乐导航_怎么看百家乐走势_全讯网官网 (中国)·官方网站

Research News

Nature Reviews Drug Discovery: targeting cancer-associated fibroblasts

Share
  • Updated: Dec 24, 2018
  • Written:
  • Edited:
Source: Sun Yat-sen Memorial Hospital
Written by: Xueman Chen
Edited by: Wang Dongmei

Recently, a Review Article entitled “Turning foes to friends: targeting cancer-associated fibroblasts” was published online in Nature Reviews Drug Discovery (IF 2018=50.17)1. Professor Erwei Song, President of Sun Yat-sen Memorial Hospital, Sun Yat-sen University, is the corresponding author, and Xueman Chen, a PhD student from his team, is the first author.

Current paradigms of cancer-centric therapeutics are usually not sufficient to eradicate the malignancy, as the cancer stroma may prompt tumor relapse and therapeutic resistance. In the past decade, a burst of knowledge on how the tumor microenvironment (TME) interacts with tumor cells has urged studies on a new cancer treatment paradigm: targeting the tumor stroma. Among all the stromal cells that populate the TME, cancer-associated fibroblasts (CAFs) are the most abundant and are critically involved in cancer progression, which render them as conspicuous stromal targets in many, if not all, solid tumors. However, without unequivocal cell-surface markers, live-cell sorting for functional and mechanistic studies on CAFs in vitro and targeting therapies towards CAFs in vivo are greatly hindered.

It is noteworthy that a previous research from Prof. Erwei Song’s team revealed CD10 and GPR77 as two specific cell-surface makers for a novel pro-tumorigenic CAF subset involved in cancer stemness and chemoresistance2. More importantly, GPR77 is a functional marker which can be directly targeted for in vivo CAF depletion. The restoration of chemosensitivity of tumor cells upon GPR77 blockade further suggests the remarkable therapeutic value of such a precise CAF-targeted strategy for cancers.


Accumulated molecular characterization of CAFs not only deepens our insights into their phenotypic heterogeneity and functional diversity, but also brings CAF-targeting therapies for cancer treatment onto the agenda. However, translating the basic research into clinical practice takes tremendous efforts and is extremely time-consuming, which makes it an urgent need for therapists and drug developers to comprehensively recognize the functional significance and molecular mechanisms of CAFs in cancers.

In this Review, Prof. Song’s team presented a full-scale overview regarding the current understanding of the hallmarks, biology and heterogeneity of CAFs, highlighting the CAF-centered intercellular crosstalk within the TME, and discussed multipronged functions of CAFs in tumor initiation, progression, metastasis and resistance to anticancer therapies. Prof. Song’s team also elaborated on the potential therapeutic strategies targeting CAFs, with an aim to accelerate the leap from bench to bedside.


References
1.  Chen, X. & Song, E. Turning foes to friends: targeting cancer-associated fibroblasts. Nature Reviews Drug Discovery (2018).
2.  Su, S., et al. CD10(+)GPR77(+) Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness. Cell (2018).

Link to the review article: www.nature.com/articles/s41573-018-0004-1
TOP
百家乐官网视| 城步| 百家乐官网和怎么算输赢| 跨国际百家乐的玩法技巧和规则| 怎么赢百家乐官网的玩法技巧和规则 | 澳门百家乐官网心德| 联众百家乐官网的玩法技巧和规则 | 百家乐官网怎么| 全讯网3| 博彩e天上人间| 百家乐官网游戏试| 百家乐官网官网站| 全讯网百导| 百家乐娱乐开户| 大发888移动版| 海尔百家乐官网的玩法技巧和规则 | 百家乐官网任你博娱乐平台| 太阳城百家乐杀猪吗| 全讯网3344111| 真人百家乐官网赌博技巧| 百家乐千术手法| 百家乐官网api| 最新棋牌游戏| 百家乐h游戏怎么玩| 猪猪棋牌游戏| 灵宝市| 百家乐最低投注| 绥德县| 百家乐桌| 百家乐官网存在千术吗| 太子娱乐城网址| 玩百家乐出千方法| 百家乐官网园有限公司| 易博彩票网| 大发888真人游戏| 肯博百家乐官网的玩法技巧和规则| 百家乐分| 百家乐官网开户最快的平台是哪家| 爱赢百家乐开户送现金| 网络百家乐棋牌| 大发888官网 ylc8|